Immunic Inc. (IMUX) reported a 24.1% increase in its stock price following a comprehensive review of its 2025 performance and the unveiling of critical upcoming milestones. The biopharmaceutical company emphasized progress in its clinical pipeline and regulatory strategy.
- IMUX shares rose 24.1% on January 12, 2026
- Phase 2 trial for IMU-838 in ulcerative colitis achieved 82% primary endpoint success
- Phase 2b trial for IMU-838 in Crohn’s disease showed 78% remission rate at week 12
- Pre-IND package submitted to FDA for new autoimmune neuropathy therapy
- Cash reserves increased 37% in 2025 to $174 million
- IND submission for new program expected by Q3 2026
Immunic Inc. (IMUX) saw its shares rise 24.1% on January 12, 2026, after releasing a detailed update on its 2025 operational and clinical achievements. The company highlighted the successful completion of Phase 2 trials for its lead candidate, IMU-838, in ulcerative colitis, with primary endpoints met in 82% of treated patients. This outcome marks a pivotal advancement in Immunic’s gastrointestinal disease portfolio. The update also outlined progress in its Phase 2b trial for IMU-838 in Crohn’s disease, where 78% of participants achieved clinical remission at week 12. Additionally, the company announced that it has submitted a pre-IND package to the U.S. Food and Drug Administration for a novel oral therapy targeting autoimmune neuropathies, with a planned IND submission by Q3 2026. These developments underscore Immunic’s expanding clinical footprint across inflammatory and immune-mediated conditions. Market analysts noted that the 24.1% stock surge reflects investor confidence in Immunic’s pipeline execution and regulatory preparedness. The company reported a 37% increase in cash reserves during 2025, reaching $174 million, which supports its ongoing trials and upcoming regulatory filings. This financial strength is seen as a critical factor in sustaining operations through late-stage development. The rally affected a broad range of stakeholders, including institutional investors, biotech-focused exchange-traded funds, and shareholders with long-term exposure to Immunic. The stock’s performance also drew attention from pharmaceutical partners evaluating potential collaboration opportunities in autoimmune disease therapeutics.